Clinical Trials
7
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:2
Phase 2:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (71.4%)Phase 1
2 (28.6%)DNS-7801 vs. Placebo in Parkinson's Disease
Phase 2
Terminated
- Conditions
- Parkinson's Disease
- Interventions
- Drug: PlaceboDrug: DNS-7801 (high dose)Drug: DNS-7801 (low-dose)
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Dart NeuroScience, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT03306329
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Long Beach, California, United States
🇺🇸SC3 Research, Pasadena, California, United States
🇺🇸Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States
DNS-3379 vs. Placebo in Stroke Rehabilitation
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Dart NeuroScience, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT03254160
- Locations
- 🇦🇺
John Hunter Hospital, New Lambton Heights, New South Wales, Australia
🇦🇺Royal North Shore Hospital, St Leonards, New South Wales, Australia
🇦🇺Sunshine Coast University Hospital, Birtinya, Queensland, Australia
HT-3951 vs. Placebo in Stroke Rehabilitation
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Dart NeuroScience, LLC
- Target Recruit Count
- 61
- Registration Number
- NCT02530307
HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)
Phase 2
Completed
- Conditions
- Age-Associated Memory Impairment (AAMI)
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Dart NeuroScience, LLC
- Target Recruit Count
- 119
- Registration Number
- NCT02013310
Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
Phase 1
Completed
- Conditions
- Healthy Volunteers (Part 1)Major Depressive Disorder (Part 2)
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- Dart NeuroScience, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01413932
- Locations
- 🇺🇸
Clinical Site, Glendale, California, United States
- Prev
- 1
- 2
- Next
News
No news found